MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Files An 8-K Regulation FD Disclosure

On December 14, 2016, MEDITE Cancer Diagnostics, Inc. (the “Company”) filed a Current Report on Form 8K which included as Exhibit 99.1 to the Current Report an investor presentation which may be presented at meetings with investors, analysts, and others, in whole or in part and possibly with modifications, during the fiscal year ending December 31, 2016 and December 31, 2017. The Exhibit 99.1 filed in the previous Current Report contained an error citing an offering which had previously been closed by the Company. The Company therefore amends the Current Report to provide the corrected Exhibit 99.1.

By filing this amendment to the Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this amended Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained in the investor presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this amendment to the Current Report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this amended Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

Exhibit Description

99.1 Investor Presentation

About MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT)
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers. MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Recent Trading Information
MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) closed its last trading session 00.000 at 0.710 with shares trading hands.